3 Cardiac Care Hospitals, Molecular Diagnostics Kits and Single-Use Medical Devices Stocks With a Strong Future Roadmap: Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure
- October 22, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure: ROE of 10.4% to 17.8% and FY22 to FY26 revenue CAGR of 16.8% to 21.0%. Prices as of 21 Oct 2026.
Quick Answer
The three healthcare technology and devices stocks to watch are Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure. Their return on equity ranges from 10.4% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 21.0%. Narayana Hrudayalaya leads on both return on equity at 17.8% and revenue growth at 21.0% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.
Medical device and diagnostics stocks let investors follow companies that treat, test and supply the tools of modern care. Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure cover cardiac care hospitals, molecular diagnostics kits and single-use medical devices.
This list covers three healthcare technology and devices stocks with complete current figures: Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Healthcare Technology and Devices Stocks?
Medical device and diagnostics stocks are listed companies that operate hospitals or make diagnostic kits and disposable devices used in treatment. Their earnings depend on patient volumes, product approvals and export demand.
Healthcare Technology and Devices Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Narayana Hrudayalaya | 1,725 | 35,603 | 43.6 | 59.6 | 17.8 | 1.29 |
| Molbio Diagnostics | 1,322.6 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
| Poly Medicure | 1,470.1 | 15,721 | 50.2 | 59.6 | 10.4 | 0.11 |
On valuation, Narayana Hrudayalaya and Poly Medicure trade at a P/E below the industry P/E, while Molbio Diagnostics trades above it, which reflects the growth the market already expects. Readers comparing healthcare technology and devices stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in healthcare technology and devices stocks can use the coming numbers to test whether growth is holding.
Why Do Healthcare Technology and Devices Stocks Have a Strong Roadmap in India?
Medical device and diagnostics stocks have a strong roadmap in India because rising health spending, wider access to testing and growing local manufacturing of devices create demand across the care chain.
- Local manufacturing. Policy support helps Indian makers of devices and test kits.
- Wider testing. Molecular tests reach more hospitals and smaller towns.
- Export markets. Disposable devices find buyers in many countries.
Why Narayana Hrudayalaya Features Among These Healthcare Technology and Devices Stocks
Among the healthcare technology and devices stocks on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.
Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.
The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6.
Roadmap: Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
What to watch: Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.
Why Molbio Diagnostics Features Among These Healthcare Technology and Devices Stocks
Among the cardiac hospital and device shares on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Why Poly Medicure Features Among These Healthcare Technology and Devices Stocks
Among the three companies on this list, Poly Medicure makes single-use medical devices such as infusion sets, syringes, catheters, blood management products and dialysis consumables, and it exports to many countries.
Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%.
In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6.
Roadmap: The company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
What to watch: Track export growth, new product approvals and plant capacity use.
Narayana Hrudayalaya vs Molbio Diagnostics vs Poly Medicure on Key Financials
The table below sets the three healthcare technology and devices stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Narayana Hrudayalaya | 3,736 | 7,996 | 21.0% | 810 | 10.1% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
| Poly Medicure | 961 | 1,995 | 20.0% | 321 | 16.1% |
Narayana Hrudayalaya posts the highest return on equity in this group at 17.8%. Narayana Hrudayalaya combines the largest FY26 revenue at Rs 7,996 crore with the fastest revenue growth, a 21.0% compound annual rate. A useful habit with healthcare technology and devices stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several diagnostic kit maker stocks instead of one name, which keeps a single result from deciding the outcome.
Key Risks to Check Before Investing in Healthcare Technology and Devices Stocks
Every theme carries risks that deserve a check before any decision. For these healthcare technology and devices stocks, the main points are: Long-term cardiac hospital and device shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study cardiac hospital and device shares.
- Approval timelines. Product launches depend on regulatory decisions that can shift.
- Pricing pressure. Competition and procurement rules can limit pricing.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter healthcare technology and devices stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Healthcare Technology and Devices Stocks
Medical device and diagnostics stocks reward investors who follow patient volumes, approvals and exports together. Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure each serve a different step in care. Based on the 21 October 2026 close, Narayana Hrudayalaya trades at Rs 1,725, Molbio Diagnostics at Rs 1,322.6 and Poly Medicure at Rs 1,470.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these healthcare technology and devices stocks to a watchlist. Peer comparison is the simplest way to judge healthcare technology and devices stocks, because sector averages show whether a company’s margins and returns are ordinary or exceptional.
Download the Univest iOS App or Univest Android App to track healthcare technology and devices stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are healthcare technology and devices stocks?
Ans. Medical device and diagnostics stocks are listed companies that operate hospitals or make diagnostic kits and disposable devices used in treatment. Their earnings depend on patient volumes, product approvals and export demand. This list looks at three of them, Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.
Which healthcare technology and devices stocks are covered in this list?
Ans. This list covers Narayana Hrudayalaya, Molbio Diagnostics and Poly Medicure. Based on the 21 October 2026 close, Narayana Hrudayalaya traded at Rs 1,725, Molbio Diagnostics at Rs 1,322.6 and Poly Medicure at Rs 1,470.1. Their return on equity ranges from 10.4% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 21.0%.
Why do healthcare technology and devices stocks have a strong future roadmap in India?
Ans. Medical device and diagnostics stocks have a strong roadmap in India because rising health spending, wider access to testing and growing local manufacturing of devices create demand across the care chain. The main drivers are as follows. Local manufacturing. Policy support helps Indian makers of devices and test kits. Wider testing. Molecular tests reach more hospitals and smaller towns. Export markets. Disposable devices find buyers in many countries. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Narayana Hrudayalaya performed financially?
Ans. Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
How has Poly Medicure performed financially?
Ans. Revenue rose from Rs 961 crore in FY22 to Rs 1,995 crore in FY26, a compound annual growth rate of 20.0%. Net profit grew from Rs 147 crore in FY22 to Rs 321 crore in FY26, which works out to a compound annual growth rate of 21.6%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 559 crore. The company has a return on equity of 10.4%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 15,721 crore. The stock trades at a P/E of 50.2, below the industry P/E of 59.6. Looking ahead, the company is adding capacity and new products, including dialysis and cardiology devices, and it is growing its presence with global hospital customers. Rising healthcare spending supports demand for disposable devices.
What risks should investors check before buying healthcare technology and devices stocks?
Ans. Investors should check a few risks before buying healthcare technology and devices stocks. Approval timelines. Product launches depend on regulatory decisions that can shift. Pricing pressure. Competition and procurement rules can limit pricing. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of healthcare technology and devices stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
